$0.362100
00.00%
At close: Jul 2, 2:53 PM EDT
15 minutes delayed
Panbela Therapeutics
PBLAOTCQB
Panbela Therapeutics (OTC:PBLA) Stock, Analyst Ratings, Price Targets, Predictions
Panbela Therapeutics Inc has a consensus price target of $9.13, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Roth MKM, and Roth MKM on April 2, 2024, March 27, 2024, and February 5, 2024. With an average price target of $18.33 between HC Wainwright & Co., Roth MKM, and Roth MKM, there's an implied 4963.06% upside for Panbela Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Roth MKM
Maxim Group
Roth Capital
1calculated from analyst ratings
Analyst Ratings for Panbela Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis | — | Reiterates | → Neutral | Get Alert |
| 05/16/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis | — | Downgrade | Buy → Neutral | Get Alert |
| 04/02/2024 | Buy Now | 1280.83% | HC Wainwright & Co. | Joseph Pantginis | $16 → $5 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 6804.17% | Roth MKM | Jonathan Aschoff | → $25 | Maintains | Buy | Get Alert |
| 02/05/2024 | Buy Now | 6804.17% | Roth MKM | Jonathan Aschoff | $500 → $25 | Maintains | Buy | Get Alert |
| 12/18/2023 | Buy Now | 6804.17% | Roth MKM | Jonathan Aschoff | → $500 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 4318.67% | HC Wainwright & Co. | Joseph Pantginis | → $320 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 4318.67% | HC Wainwright & Co. | Joseph Pantginis | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | 4318.67% | HC Wainwright & Co. | Joseph Pantginis | → $320 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2023 | Buy Now | 4318.67% | HC Wainwright & Co. | Joseph Pantginis | → $320 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 4318.67% | HC Wainwright & Co. | Joseph Pantginis | $140 → $320 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 1833.17% | HC Wainwright & Co. | Joseph Pantginis | → $4200 | Reiterates | → Buy | Get Alert |
| 04/26/2023 | Buy Now | 1833.17% | HC Wainwright & Co. | Joseph Pantginis | → $4200 | Initiates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | 314.25% | Maxim Group | Jason McCarthy | → $900 | Upgrade | Hold → Buy | Get Alert |
| 01/31/2023 | Buy Now | 2661.67% | Roth Capital | Jonathan Aschoff | → $6000 | Reinstates | → Buy | Get Alert |
| 10/12/2022 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Panbela Therapeutics (PBLA) stock?
The latest price target for Panbela Therapeutics (OTCQB:PBLA) was reported by HC Wainwright & Co. on June 24, 2024. The analyst firm set a price target for $0.00 expecting PBLA to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
The latest analyst rating for Panbela Therapeutics (OTCQB:PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their neutral rating.
When was the last upgrade for Panbela Therapeutics (PBLA)?
The last upgrade for Panbela Therapeutics Inc happened on March 20, 2023 when Maxim Group raised their price target to $1.5. Maxim Group previously had a hold for Panbela Therapeutics Inc.
When was the last downgrade for Panbela Therapeutics (PBLA)?
The last downgrade for Panbela Therapeutics Inc happened on May 16, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Panbela Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on June 24, 2024 so you should expect the next rating to be made available sometime around June 24, 2025.
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Panbela Therapeutics (PBLA) is trading at is $0.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.